Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir

Kevin Robertson¹ · Paul Maruff² · Lisa L. Ross³ · David Wohl⁴ · Catherine B Small⁵,⁶ · Howard Edelstein⁷ · Mark S. Shaheer³

Received: 19 April 2018 / Revised: 6 September 2018 / Accepted: 12 September 2018 / Published online: 8 October 2018
© The Author(s) 2018

Abstract
Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, learning, and working memory in 293 HIV-1-infected, ART-experienced, and virologically suppressed adults. The ASSURE study randomized participants 1:2 to remain on tenofovir/emtricitabine (TDF/FTC) and ritonavir-boosted atazanavir (ATV/r) or simplify to abacavir/lamivudine + atazanavir (ABC/3TC + ATV). Neurocognitive z-scores were computed using demographically adjusted normative data and were classified as “impaired” (defined as either a z-score ≤ −2 or having 2 or more standardized individual test z-scores ≤ −1); while higher scores (equaling better performance) were classified as “normal”. By z-scores, 54.7% of participants had impaired neurocognition at baseline and 50.2% at week 48. There were no significant differences (p < 0.05) in the baseline-adjusted performance between treatment groups for any individual test or by z-score. Specific demographic and medical risk factors were evaluated by univariate analysis for impact on neurocognitive performance. Factors with p < 0.10 were evaluated by backwards regression analysis to identify neurocognition-correlated factors after accounting for treatment, assessment, and baseline. Four risk factors at baseline for impaired neurocognition were initially identified: lower CD4 nadir lymphocyte counts, higher Framingham risk scores, and interleukin-6 levels, and a history of psychiatric disorder not otherwise specified, however none were found to moderate the effect of treatment on neurocognition. In this aviremic, treatment-experienced population, baseline-adjusted neurocognitive function remained stable and equivalent over 48 weeks with both TDF/FTC + ATV/r-treated and in the ART-simplified ABC/3TC + ATV treatment groups.

Keywords HIV · HIV-associated neurocognitive disorder · Cogstate · Computerized battery · HIV-cognitive disorder

Introduction
The use of ART in patients infected with HIV-1 has greatly increased survival and decreased the incidence of HIV-1 and AIDS-associated conditions, such as Kaposi’s sarcoma, Pneumocystis jirovecii pneumonia, and HIV-associated dementia. However, milder HIV-associated neurological disorders (HAND) have been noted in patients on ART, including those with suppressed viral loads. (Zhou and Saksena 2013; Simioni et al. 2010; Heaton et al. 2010; Saylor et al. 2016). Less is known about how the choice of ART impacts the likelihood of HAND in aviremic patients. Simplification studies provide a unique opportunity to investigate this issue, particularly given that current treatment guidelines, such as those from the US Department of Health and Human Services
Neurocognition was measured in the ASSURE study with a computerized cognitive test battery, the Cogstate Brief Battery (CBB; Cogstate; Melbourne, Australia). The CBB includes four cognitive tests which assess psychomotor function, attention, learning, and working memory which have previously been described in detail (Cysique et al. 2006). The CBB requires approximately 15 min for completion in HIV-infected adults; a single performance measure is generated for each of these four tests. Analyses of the neurocognitive data were conducted on the intent-to-treat exposed (ITT-E) population. All participants completed the entire CBB at a pre-baseline familiarization assessment, a baseline assessment and then an assessment at the week 24, week 48, and if an early withdrawal from the study occurred. Data from the familiarization visit was not used in the analyses.

To provide a measure of global neurocognition, a $z$-score was derived from the four tests in the CBB for each participant at each assessment. Each time, a study participant completed the CBB; their data were uploaded to a secure database and processed to provide the four primary outcome measures. Each outcome measure was then standardized using demographic-adjusted normative data and summed to compute a $z$-score, which was a neuropsychological composite of the four tests that was used to define global neurocognition.

**Methods**

**Clinical study description**

Briefly, ASSURE (EPZ113734; NCT01102972) was a prospective, randomized, multicenter, open-label, and phase IV study that enrolled HIV-1-infected, ART-experienced adults (≥18 years of age) who had received a once-daily regimen of TDF/FTC 300 mg/200 mg (Gilead Sciences, Foster City, CA, USA) + ATV 300 mg (Bristol-Myers Squibb, Princeton, NJ, USA) boosted with ritonavir 100 mg (AbbVie, Chicago, IL, USA) for ≥6 months and had HIV-1 RNA ≤ 75 copies/mL for at least 28 days prior to the screening visit. As part of the inclusion and exclusion criteria, participants were excluded if they were HLA-B*5701-positive or had prior abacavir exposure, active CDC clinical category C disease, ongoing clinically relevant hepatitis and/or chronic hepatitis B infection (HBsAg+), or a creatinine clearance < 50 mL/min via the Cockcroft-Gault method. Additional information regarding all inclusion/exclusion criteria, methods, and endpoints, including a link to the protocol, is available in the 24-week efficacy results publication (Wohl et al. 2014). All participants provided written informed consent to participate in the study, and the protocol was approved by the institutional review board for each study site.

After stratification by prior ART experience (TDF/FTC + ATV/r as the initial regimen or as the first/s switch regimen), eligible participants were randomized 2:1 to simplify their regimen to once-daily ABC/3TC 600 mg/300 mg (ViiV Healthcare, Research Triangle Park, NC, USA) plus ATV 600 mg or remain on TDF/FTC + ATV/r. The ASSURE study was powered to evaluate its primary endpoint, which was the proportion of participants with HIV-1 RNA < 50 copies/mL at week 24 by the time to loss of virologic failure (TLOVR) algorithm. Eighty-seven percent of participants in both treatment groups successfully maintained HIV-1 RNA < 50 copies/mL at week 24, demonstrating non-inferiority of simplification to ABC/3TC + ATV compared with continuation of TDF/FTC + ATV/r (Wohl et al. 2014). Results at week 48 were similar, with HIV-1 RNA < 50 copies/mL in 76% of participants taking ABC/3TC + ATV and 79% of participants taking TDF/FTC + ATV/r (Wohl et al. 2016).

**Neurocognitive assessments**
For each assessment, each participant’s neurocognition was categorized as either “impaired” (defined as either a z-score ≤ −2 or having two or more standardized individual test z-scores ≤ −1), while higher scores (equating to better performance) were classified as “normal.” The normative dataset used as a comparator in this analysis was obtained by Cogstate from a healthy, non-HIV-infected population. The normative dataset used in this analysis was stratified by age group, and was similar in composition to the ASSURE study participants in terms of age and gender distributions and where possible, was of similar ethnicity; as previously been described (Haddow et al. 2017).

**Statistical analysis**

The primary exploratory analysis objective was to determine the extent to which 24 and 48 weeks of treatment with ATV + ABC/3TC versus ATV/r + TDF/FTC was associated with changes in neurocognition in the ITT-E population. Study participants must have attempted the baseline and either one or both of the week 24 and week 48 assessments to be included in analyses of neurocognition. Data were analyzed using a series of linear mixed models in which the baseline was modeled as a covariate and treatment group (ABC/3TC + ATV and TDF/FTC + ATV/r) and assessment were modeled as fixed factors. The z-scores, as well as the scores from each of the CBB tests, were modeled separately as the dependent variable. Any early withdrawal or unscheduled visit assessment done between week 12 and week 35 was reclassified into the week 24 assessment group; any assessment performed at week 36 or beyond was classified as week 48 assessments. Through week 48, results for the two treatment groups were compared using an analysis of covariance (ANCOVA) adjusted for baseline performance scores. Cohen’s d was calculated to estimate the magnitude of the differences between the two treatment groups; effect sizes of 0.2–0.4 are considered mild, 0.5–0.7 considered moderate, and ≥0.8 considered large (Cohen 1988). To validate the model assumption that the relationship between baseline and outcome were parallel for each treatment group, a baseline by treatment interaction was included in the model and removed only if the corresponding p value was > 0.05. A secondary analysis was also conducted to determine the extent to which 24 and 48 weeks of treatment with ATV + ABC/3TC versus ATV/r + TDF/FTC was associated with changes in neurocognition but restricted to the population of study participants with virologic suppression. The analysis population included participants with z-scores at the 24 or 48 week assessment visits and who had HIV-1 RNA < 50 copies/mL, as assessed by the time to loss of virologic response (TLOVR) algorithm, and the analysis compared the measures of cognition by treatment group and the effect sizes for treatment differences.

In another secondary analysis, the potential association between selected covariate risk factors (body mass index, CD4 nadir lymphocyte count, high-sensitivity C-reactive protein, depression, type I diabetes, type II diabetes, Framingham 10-year coronary heart disease risk score, interleukin 6 level, psychiatric disorders not otherwise specified, study stratification, the total weighted CNS penetration effectiveness (TWCPE) score), and neurocognitive performance (impaired versus normal) were examined using a two-tiered approach. First, a univariate analysis was conducted on each of the factors to determine their relationship to neurocognitive performance. Factors classified as different (i.e., p value < 0.10) were then submitted to a backwards regression process to identify those that correlated most strongly with neurocognition, after accounting for all the other relevant exploratory factors. The first stage, the univariate analyses, was conducted to identify the variables to be used in the backwards regression process. This method was employed to avoid an over-saturated model at the start of the backwards regression process. The effect of the demographic and medical covariates on performance on the Cogstate battery was further investigated by determining which factors were associated with a change in performance over time for each Cogstate test. All data analyses were conducted using Statistical Analytic Software (SAS v9.2; Cary, North Carolina, United States).

**Results**

Almost all (293/296; 99%) of the ASSURE study participants were included after having provided valid and complete baseline data for one or more of the four CBB tests. By the same criterion, 92% (272/296) of study participants completed an assessment at week 24 and 81% (240/296) at week 48.

All data received was submitted to test completion and data integrity checks (performed by Cogstate) to ensure that the data reflected performance on the test and that the demands of the test were understood. The analysis showed that the test battery was well tolerated in this study population; 99.67% of data were analyzed with ten test completion failures. After data cleaning, a total of 1089 tests were received across the pre-baseline, baseline, week 24, week 48, early withdrawal, and unscheduled visit assessments. The pre-specified data integrity checks were passed by 94.3% of the data at the analysis points (baseline, week 24, week 48, or withdrawal visits). Based on the high proportion of scores that met the integrity criteria, the entire data set was included in the ITT-E analysis.

**Study population**

The enrolled participants were predominantly male and white (Table 1), although more than a third were African-American. All participants were from sites in the USA and Puerto Rico. More than 25% of participants identified as Hispanic or Latino.
At baseline, nearly half of the participants had taken ≥1 ART regimen before starting TDF/FTC + ATV/r, and the median time on ART was approximately 3 years. The mean z-scores calculated at the baseline assessment for each of the two treatment groups were not significantly different, with a mean of −1.155 (standard deviation 1.087; n = 180) for the ABC/3TC + ATV treatment group and a mean of −1.1755 (standard deviation 1.136, n = 83) for the TDF/FTC + ATV/r treatment group.

At the start of the ASSURE study, 54.7% of the ART-experienced study participants were assessed as having impaired neurocognition (Table 2) and 50% or more of all participants were classified as having impaired neurocognition in the post-baseline assessments. While the overall proportions remained similar, the neurocognitive assessments for an individual participant did not always remain static. In an evaluation of the change from baseline (CFB) results at the week 24 assessment, approximately 25% of participant assessments had a change from their baseline classification status (from normal to impaired or from impaired to normal). Overall, a small proportion (13.3%) of participants went from a classification of impaired at baseline to normal at week 48, while a smaller proportion (8.7%) saw a change from normal to impaired neurocognition. Overall, at week 48, 50% of participants were classified as normal, while 50% were classified as impaired, similar to the proportions observed for the study population at baseline.

The results for each of the individual tests and the z-scores were obtained for study participants with evaluable data and tabulated by treatment group (Table 3). There were no significant differences in the baseline-adjusted performance between the participants taking ABC/3TC + ATV and those taking TDF/FTC + ATV/r for any individual neurocognitive test or for the composite z-score. Consideration of the effect sizes indicated the magnitude for these group differences was uniformly small (i.e., d < 0.2).

As not all participants remained virologically suppressed through 48 weeks in either treatment group, a secondary analysis assessed whether there was any differential impact by treatment group on neurocognition, as assessed by the z-scores, for those participants who maintained virologic suppression (HIV-RNA < 50 copies/mL) through 24 or 48 weeks. By treatment group, for the comparison of ATV + ABC/3TC to ATV/r + TDF/FTC, there were 143 and 73 participants, respectively at week 24 who had remained virologically suppressed and had neurocognitive test results at baseline and week 24 and 142 and 70 virologically suppressed participants, respectively at week 48 with z-scores at baseline and week 48. The adjusted mean difference and 95% upper and lower CI for the comparison at weeks 24 and 48 were −0.195 (−0.435; 0.045) and 0.097 (−0.332; 0.137), respectively. Cohen’s d effect size at weeks 24 and 48 were −0.230 and −0.120, and the p values were 0.111 and 0.414, respectively. Similar results were observed for analyses performed for each of the individual tests within the test battery and for all measures of neurocognition, the effect sizes for treatment differences remained small in magnitude and none were statistically significant.

**Covariate analyses**

Analysis of the demographic and medical factors associated with a classification of impaired neurocognitive performance at the baseline assessment was performed to explore whether specific demographic or illness-related variables could moderate the effect of treatment. For the detection test, while the regression analyses identified high-sensitivity C-reactive protein as a covariate of interest, it no longer had any significance on the relationship between treatment and neurocognition after the backwards regression was conducted. For the identification test, the covariates psychiatric disorder not otherwise specified and CD4 nadir lymphocyte cell counts were found to be significant at the alpha level of 0.1 and remained in the model after baseline, treatment and visit were added. After adjusting for psychiatric disorder not otherwise specified and CD4 nadir lymphocyte count, the effect of treatment on neurocognition was similar (p value = 0.234 vs. p value = 0.178). For the one card-learning test, psychiatric disorder not otherwise specified, type II diabetes, stratification, and
depression were significant after the univariate regression, however none of these covariates remained significant after the backwards regression process. For the one back test, depression was significant in the univariate analysis and remained in the model when treatment, baseline and visit were controlled. However, after adjusting for the effect of depression history on neurocognitive performance, the effect of treatment on neurocognition was similar (p value = 0.340 vs. p value = 0.571). None of the covariates were significant in the univariate analysis for the z-score (all p values > 0.1).

When performance on the neurocognitive tests at baseline was considered categorically as being impaired or normal (Table 4), differences were found for four factors: lower CD4 lymphocyte count at nadir, higher scores on the Framingham risk factor and higher values for interleukin 6, and having a history of psychiatric disorder not otherwise specified. For the continuous variables (Framingham risk, CD4 nadir lymphocyte count, and interleukin 6), the magnitude of differences in covariate score between impaired and normal neurocognition was expressed using Cohen’s d.

| Test Population | Week 48 adjusted mean difference (95% CI) | Cohen’s $d$ effect size | p value |
|-----------------|------------------------------------------|-------------------------|---------|
| **Week 24**     |                                          |                         |         |
| Detection       | 0.004 (−0.026, 0.033)                     | 0.032                   | 0.811   |
| Identification  | 0.015 (−0.006, 0.036)                     | 0.183                   | 0.172   |
| Once card learning | −0.006 (−0.030, 0.018)                  | −0.062                  | 0.639   |
| One back memory | 0.012 (−0.012, 0.036)                    | 0.134                   | 0.316   |
| z-score         | −0.128 (−0.39, 0.094)                    | −0.152                  | 0.257   |
| **Week 48**     |                                          |                         |         |
| Detection       | 0.006 (−0.026, 0.037)                     | 0.050                   | 0.721   |
| Identification  | 0.011 (−0.010, 0.032)                     | 0.147                   | 0.291   |
| Once card learning | 0.003 (−0.027, 0.032)                  | 0.024                   | 0.865   |
| One back memory | −0.001 (−0.026, 0.023)                   | −0.013                  | 0.923   |
| z-score         | −0.054 (−0.281, 0.172)                   | −0.066                  | 0.638   |

ABC/3TC, abacavir/lamivudine; ATV, atazanavir; ATV/r, atazanavir/ritonavir; CI, confidence interval; TDF/FTC, tenofovir/emtricitabine

*A negative difference score and negative effect size indicate that ATV + ABC/3TC performance was improved over ATV/r + TDF/FTC

*B A positive difference score and positive effect size indicate that ATV + ABC/3TC performance was improved over ATV/r + TDF/FTC
Table 4  Risk factors by participants classified as either normal or impaired neurocognition at the baseline assessment

| Risk factor (category) | Neurocognitive classification | Mean a | Standard deviation | Mean difference | Magnitude of difference b | p value c |
|------------------------|-------------------------------|--------|--------------------|----------------|--------------------------|-----------|
| Body mass index        | Normal                        | 28.559 | 7.198              |                |                          |           |
| Body mass index        | Impaired                      | 28.419 | 6.065              | −0.140         | −0.021                   | 0.706     |
| CD4 nadir              | Normal                        | 320.214| 226.5              |                |                          |           |
| CD4 nadir              | Impaired                      | 289.172| 192.8              | −31.042        | −0.148                   | 0.011     |
| High-sensitivity C-reactive protein | Normal          | 3.957  | 9.735              |                |                          |           |
| High-sensitivity C-reactive protein | Impaired    | 3.392  | 5.894              | −0.564         | −0.072                   | 0.214     |
| Depression (current)   | Normal                        | 0.094  |                    |                |                          | 0.191     |
| Depression (past)      | Normal                        | 0.049  |                    |                |                          |           |
| Depression (no medical condition) | Normal | 0.004  |                    |                |                          |           |
| Depression (current)   | Impaired                      | 0.166  |                    | 1.718          | (0.96, 3.06)             |           |
| Depression (past)      | Impaired                      | 0.068  |                    | 1.351          | (0.62, 2.94)             |           |
| Depression (no medical condition) | Impaired  | 0.313  |                    |                |                          |           |
| Diabetes type II (current) | Normal                  | 0.026  |                    |                |                          | 0.274     |
| Diabetes type II (current) | Impaired                | 0.026  |                    | 0.804          | (0.27, 2.36)             |           |
| Diabetes type II (no medical condition) | Normal  | 0.521  |                    |                |                          |           |
| Diabetes type II (current) | Normal                  | 2.452  | 3.350              |                |                          |           |
| Diabetes type II (no medical condition) | Impaired  | 3.517  | 5.748              | 1.065          | 0.222                    | 0.000     |
| Framingham score d     | Normal                        | 3.161  | 4.152              |                |                          |           |
| Framingham score d     | Impaired                      | 3.757  | 5.525              | 0.597          | 0.120                    | 0.030     |
| Interleukin 6           | Normal                        | 2.452  | 3.350              |                |                          |           |
| Interleukin 6           | Impaired                      | 3.517  | 5.748              | 1.065          | 0.222                    | 0.000     |
| Psychiatric disorders f (current) | Normal | 0.094  |                    |                |                          | 0.030     |
| Psychiatric disorders f (current) | Normal | 0.004  |                    |                |                          |           |
| Psychiatric disorders f (no medical condition) | Normal  | 0.351  |                    |                |                          |           |
| Psychiatric disorders f (past) | Normal             | 0.102  |                    | 0.948          | (0.51, 1.75)             |           |
| Psychiatric disorders f (past) | Normal             | 0.045  |                    | 10.528         | (1.34, 82.51)            |           |
| Psychiatric disorders f (no medical condition) | Normal  | 0.400  |                    |                |                          |           |
| Stratification (initial antiretroviral regimen: ATV/r + TDF/FTC) | Normal          | 0.294  |                    |                |                          | 0.657     |
| Stratification (initial antiretroviral regimen: NNRTI + TDF/FTC) | Normal          | 0.158  |                    |                |                          | 0.657     |
| Stratification (initial antiretroviral regimen: ATV/r + TDF/FTC) | Impaired       | 0.370  |                    |                |                          |           |
| Stratification (initial antiretroviral regimen: NNRTI + TDF/FTC) | Normal          | 0.177  | 1.123              | (0.67, 1.87)   | 0.657                    |           |
| TWCPF e                 | Normal                        | 6.129  | 0.693              |                |                          |           |
| TWCPF e                 | Impaired                      | 6.091  | 0.420              | −0.038         | −0.067                   | 0.281     |

a Rather than mean, the proportion, where relevant, was calculated

b The magnitude of difference was calculated either by Cohen’s d or odds ratio for odds of impaired neurocognition; for the odds ratio, these were calculated as the odds of impaired neurocognitive performance with regard to a reference category. For depression, psychiatric disorders and diabetes type 2, the reference category is “no medical condition.” For stratification, the reference category is “Initial antiretroviral regimen: ATV/r + TDF/FTC.” Where there is not enough data in the relevant category, odds ratios are not calculated. The 95% confidence intervals for the odds ratios are also given

c p values were calculated by Student’s t test or by chi-squared for categorical variables (H0:no difference in means)

d 10-year coronary heart disease Framingham risk score

e This variable encompassed all psychiatric disorders not otherwise specified

f Total weighted cerebrospinal fluid penetration effectiveness score
the categorical variable history of psychiatric disorder, the effect was expressed by computing the odds of impaired neurocognition with a history of psychiatric disorder compared to no medical condition. The magnitudes of differences in covariates for Framingham risk, CD4 nadir lymphocyte count, and interleukin 6 covariates were small ($d < 0.2$). However, a history of psychiatric disorder increased the odds of current classification of impaired neurocognition tenfold.

The effect of the demographic and medical covariates on performance for the CBB was further investigated by determining which factors were associated with change in performance over time for each Cogstate test. Any significant factors that were identified were added to a backwards regression model with that included terms for the baseline, assessment, and for treatment. Demographic and medical covariates were considered to have influenced performance if the relationship with change in performance remained statistically significant in the backwards regression model. These analyses identified no covariate that influenced a change in performance on the detection test, one card-learning test, or the $z$-score neurocognitive measurement. For the identification test, a history of psychiatric disorder not otherwise specified and CD4 nadir lymphocyte count was associated with cognitive performance after taking into account the baseline, assessment, and treatment effects. For the one back test, a history of depression was associated with cognitive performance after taking into account the baseline assessment as well as treatment effects. In both cases, the study treatments had no effect on neurocognition.

Taken together, these analyses indicate that after adjusting for baseline and relevant demographic and medical covariates there were no differences in performance between the ATV + ABC/3TC and ATV/r + TDF/FTC treatment arms for any of the Cogstate outcomes. While these risk factors were identified to be associated with neurocognitive performance over all assessments (baseline, week 24 or 48), none of these risk factors were found to moderate the effect of treatment on neurocognition.

### Discussion

The analysis of the assessment data indicated that the neurocognitive test battery was well tolerated in the USA/Puerto Rican study population and that performance on the battery was in accord with requirements, based on the very low rates of missing data and failure of data integrity across all study treatments and assessments. The estimates of within-participant variability in performance were also consistent with those observed in previous studies of healthy adults performing the same Cogstate test battery. With levels of neurocognition taken into account, we observed no difference between the ATV + ABC/3TC and ATV/r + TDF/FTC treatment groups in psychomotor function, attention, working memory, or memory and also for a composite measure of these ($z$-score) which provided an index of general neurocognition. These results demonstrated that in this population, participants in the ATV + ABC/3TC treatment group were able to reduce their overall number of prescribed ART medications and simplify to an unboosted ART regimen with no negative impact on neurocognition. In all cases, the magnitude of the differences between treatment groups in baseline-adjusted group mean performance at the 48-week assessment were, by convention, trivial (i.e., effect sizes less than 0.2). Hence, when considered with the large sample size, these very small group differences suggest strongly the absence of any statistical significance or treatment terms in the analysis reflected that groups were truly not different, as opposed to arising from any low statistical power. Similarly, a secondary analysis evaluated the effect of the treatment simplification at the 24 and 48 week time points for those participants who had maintained good virologic suppression (HIV-RNA < 50 copies/mL). When the analysis was restricted to include only this virologically suppressed population and compared the two treatment groups, the conclusions from the intention to treat analysis remained unchanged. For all measures of cognition, the effect sizes for treatment differences remained small in magnitude and none were statistically significant.

Over half (54.7%) of this virologically suppressed (HIV-RNA < 75 copies/mL) study, population had impaired neurocognition at baseline. The reason for this increased rate of cognitive impairment is unclear and may reflect social or demographic characteristics of the sample itself, or some consequence of involvement in this study. While this classification enabled the comparison of the effects of the study treatments, the estimates of cognitive impairment observed in this study may not be reflective of cognitive impairment in the general population of HIV-infected, ART-experienced adults. The rates of impaired neurocognition reported for HIV-infected adults vary by study, and the rates observed in this analysis are consistent with some, but not all, studies. For example, one study enrolled 50 patients with HIV-1 RNA < 50 copies/mL and no self-identified neurocognitive impairment concerns at screening, however subsequent detailed neuropsychological testing with multiple assessments demonstrated that 32 (64%) had some level of neurocognitive dysfunction (Simioni et al. 2010). Another study in aviremic patients reported that depending on the assessment method used, 32 to 51% of their study population could be classified as having neurocognitive impairment (Winton et al. 2010). Two additional studies (Cysique et al. 2011; Heaton et al. 2010) reported similar percentages of patients with impaired neurocognition using detailed neuropsychological testing, of 42% (49/116) and 52% (814/1555), respectively, although in these studies, not all participants were virologically suppressed (60% and 41%, respectively). Comparatively, lower rates of neurocognitive impairment (19%; 19/101) have been observed in an eight test version of the Cogstate battery in
virologically suppressed patients (HIV-1 RNA < 50 copies/mL); the authors suggested that as the population under evaluation was a primarily older Caucasian population (median age 53 years; median time since HIV diagnosis 14 years), and could represent a “survivor” subgroup with advanced clinical presentation (Garvey et al. 2011).

Numerous studies have evaluated whether specific antiretroviral drugs or ART regimens, especially in patients with virologic suppression can impact neurocognitive function or what specific medical or demographic factors may impact neurocognitive function or the level of HIV-1 RNA in the CNS, but such studies have yielded mixed results (Arenas-Pinto et al. 2016; Cusini et al. 2013; Cysique et al. 2004; De Luca et al. 2002; Ellis et al. 2011; Giancola et al. 2006; Marra et al. 2009; Munoz-Moreno et al. 2008; Robertson et al. 2004, 2007, 2016; Smurzynski et al. 2011; Winston et al. 2010, 2013). In this ASSURE analysis, neurocognitive performance within treatment groups (TDF/FTC + ATV/r or ABC/3TC + ATV) remained stable over the 48 weeks of treatment and there was no significant difference between treatment groups in neurocognitive performance over the 48 week treatment period. While four risk factors at baseline were significantly associated with impaired neurocognitive performance on specific tests or when performance was assessed categorically, after adjusting for baseline and relevant demographic and medical covariates, there were no differences in performance between the ATV + ABC/3TC and ATV/r + TDF/FTC treatment groups for any of the Cogstate outcomes.

Conclusions

In this aviremic, treatment-experienced population, there were no neurocognitive differences in the performance between the ATV + ABC/3TC and ATV/r + TDF/FTC treatment groups; the baseline-adjusted neurocognitive function remained stable and equivalent over 48 weeks with both treatment regimens.

Acknowledgments The authors would like to thank all of the study participants and their families; the study investigators, and their staff; the extended GSK/ViiV study team, especially M Bomar, H Zhao, I Minto, and D Margolis; the Cogstate team members C Baker, C Durkin, and K Jopling; and to all of the ASSURE study investigators, including Drs. Bartczak, Benson, Bhatti, Brachman, Bredeck, Brennan, Clay, Colon, Coulston, Cunningham, De Jesus, Edelstein, Felizarta, Gulick, Hagnis, Hanna, Henry, Houblou, Kinder, Kumar, Lalla-Reddy, LaMarca, McCurdy, Melendez-Rivera, Mills, Montoya, Nahass, Osiyemi, Ramgopal, Santiago, Saenz, Scarsella, Schrader, Shamblaw, Siegal, Slim, Sloan, Vanig, Ward, Warner, Weinberg, Wohlfeiler and Young, and their site staff.

Author contribution Substantial contributions to study conception and design were made by K.R., P.M., L.L.R., D.A.W., and M.S.S. Substantial contributions to the analysis and interpretation of the data were made by P.M., K.R., and L.L.R. Substantial contributions to acquisition of clinical study data were made by D.A.W., C.B.S., and H.E. All authors (C.B.S., D.A.W., H.E., K.R., L.L.R., P.M., and M.S.S) had full access to the data and vouch for the accuracy and completeness of the data and analyses. The manuscript was written and approved by all of the authors, each of whom contributed to the drafts and revisions.

Funding The study was funded by ViiV Healthcare. The sponsor developed the study design with input from prospective investigators.

Compliance with ethical standards

All participants provided written informed consent to participate in the study, and the protocol was approved by the institutional review board for each study site.

Disclosures Funding for this study was provided by ViiV Healthcare. During the conduct of the study, K.R. received consultancy fees and/or research funding from GlaxoSmithKline and ViiV Healthcare. P.M. is an employee of Cogstate Ltd. D.A.W. participated in advisory boards convened by Gilead Sciences and Janssen Therapeutics. Merck and Co., Gilead Sciences, and GlaxoSmithKline have provided the University of North Carolina with funding for his research. C.B.S. received consultancy fees and/or research funding from GlaxoSmithKline, ViiV Healthcare. Merck, Schering-Plough, and Abbott. H.E. is an employee of the Alameda Health System/Highland Hospital. L.L.R and M.S.S. are employees of ViiV Healthcare.

Conflicts of interest L.L.R and M.S.S are both employees of ViiV Healthcare; P.M. is an employee of Cogstate. K.R. and H.E. have no conflicts of interest. C.B.S. has received consultancy fees and/or research funding from GlaxoSmithKline and ViiV Healthcare. GlaxoSmithKline has provided the University of North Carolina at Chapel Hill with funding for D.A.W.’s research.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Arenas-Pinto A, Stohr W, Jager R, Haddow L, Clarke A, Johnson M, Chen F, Winston A, Gidi C, Thust S, Trombin R, Caims J, Solanky BS, Golay X, Paton NI, PIVOT Neurocognitive sub-study Team (2016) Neurocognitive function and neuroimaging markers in virologically suppressed HIV-positive patients randomized to ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional substudy from the PIVOT trial. Clin Infect Dis 63:257–264. https://doi.org/10.1093/cid/ciw279
Bloch M, Kanninga J, Jayewardene A, Bailey M, Carberry A, Vincent T, Quan D, Maruff P, Brew B, Cysique LA (2016) A screening strategy for HIV-associated neurocognitive disorders that accurately identifies patients requiring neurological review. Clin Infect Dis 63:687–693. https://doi.org/10.1093/cid/ciw399
Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, New Jersey
Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF, Swiss HIV Cohort Study (2013) Higher CNS penetration-
effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 62:28–35. https://doi.org/10.1097/QAI0b013e318274e2b0

Cysique LA, Maruff P, Brew BJ (2004) Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 61:1699–1704. https://doi.org/10.1001/archneur.61.11.1699

Cysique LA, Maruff P, Darby D, Brew BJ (2006) The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 21:185–194. https://doi.org/10.1016/j.acn.2005.07.011

Cysique LA, Maruff P, Buin MP, Wright E, Brew BJ (2011) HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci 23:83–89. https://doi.org/10.1176/jnp.23.1.jnp.83

De Luca A, Giancola ML, Ammassari A, Ortona L (2002) Correlates of independent HIV-1 replications in the CNS and of its control by antiretrovirals. Neurology 59:342–347

DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (2018) Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 4, 2018

Ellis RJ, Badiee J, Vaida F, Winston A (2011) Low rates of neurocognitive impairment in subjects with mild-to-moderate Alzheimer disease. Curr Alzheimer Res 11:47–58

Elion R, Berger D, Richmond G, Sension M, DeJesus E, Cimoch P, St Clair M, Yau L, Ha B, Coll102060 Study Team (2010) Simplified maintenance treatment with abacavir/lamivudine and atazanavir after discontinuation of ritonavir. HIV Clin Trials 11:170–173. https://doi.org/10.1310/hct1103-170

Ellis RJ, Badiee J, Vaida F, Letendre SL, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur JC, Robertson KR, Miyahara S, Lee A, Brown TT, Chan ES, Berzins B, Robertson K, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. J Neuropsychiatry Clin Neurosci 19:338–347. https://doi.org/10.1097/QAD.0b013e32804f3d68

Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe FC, Gilson R, Speakman A, Antinori A, Balestra P, Bruun T, Gerstoft J, Nielsen L, Vassilenko A, Collins S, Rodger AJ, Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group (2017) Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients. AIDS Behav 22:1573–1583. https://doi.org/10.1007/s10461-017-1683-z

Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindh M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75:2087–2096. https://doi.org/10.1212/WNL.0b013e318200d727

Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodrigue B, Coombs RW, Schifitto G, McArthur JC, Robertson K, AIDS Clinical Trials Group 736 Study Team (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366. https://doi.org/10.1097/QAD.0b013e32832c4152

Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH (2009) Validity of theCogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 24:165–178. https://doi.org/10.1093/arclin/acp010

Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Pérez-Alvarez N, Moltó J, Gómez G, Clotet B (2008) Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retrovir 24:1301–1307. https://doi.org/10.1089/aaid.2007.0310

Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM, NEAT Unboosted Atazanavir Cohort Study Group (2011) Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virologic suppression under antiretroviral therapy. J Antimicrob Chemother 66:2372–2378. https://doi.org/10.1093/jac/dkr316

Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD (2004) Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 36:562–566

Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915–1921. https://doi.org/10.1097/QAD.0b013e32828e4e27

Robertson KR, Miyahara S, Lee A, Brown TT, Chan ES, Berzins B, Rusin D, Eron JJ, Taiwo BO, AIDS Clinical Trials Group (ACTG) 5303 team (2016) Neurocognition with maraviroc compared with tenofovir in HIV. AIDS 30:2315–2321. https://doi.org/10.1097/QAD.0000000000001189

Santos JR, Molto J, Llibre JM, Pérez N, Capitán MC, CLOTET B (2009) Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice. HIV Clin Trials 10:129–134. https://doi.org/10.1007/s10461-010-0003-x

Saylor D, Dickens AM, Sacktor N, Saylor D, Dickens A, Sacktor N, Haughney N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-associated neurocognitive disorder- pathogenesis and prospects for treatment. Nat Rev Neurol 12:234–248. https://doi.org/10.1038/nrneurol.2016.27

Sension M, de Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, González-García J, Donnelly A, Pirhi P, Ledesma E, McGrath D,
067 Study Group (2009) Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 51:153–162. https://doi.org/10.1097/QAI.0b013e3181a5701c

Simioni S, Cavassini M, Annoni JM, Rimbaud Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250. https://doi.org/10.1097/QAI.0b013e3283354a7b

Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25:357–365. https://doi.org/10.1097/QAD.0b013e32834171f8

Soriano V, Garcia-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morell J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J (2008) Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viremia: final results of the SLOAT trial. J Antimicrob Chemother 61:200–205. https://doi.org/10.1093/jac/dkm413

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS, ARIES study team (2010) Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 24:2019–2027. https://doi.org/10.1097/QAD.0b013e328333beeb

Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA, Altair Study Group (2010) Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1–infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 50:920–929. https://doi.org/10.1086/650743

Winston A, Arenas-Pinto A, Stohr W, Fisher M, Orkin CM, Adorogba K, De Burgh-Thomas A, O’Farrell N, Lacey CJ, Leen C, Dunn D, Paton NI, PIVOT Trial Team (2013) Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One 8:e61949. https://doi.org/10.1371/journal.pone.0061949

Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA, ALTAIR Study Group (2015) Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. PLoS One 10:e0118608. https://doi.org/10.1371/journal.pone.0118608

Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross L, Shaefer MS (2014) Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One 9:e96187. https://doi.org/10.1371/journal.pone.0096187

Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross L, Shaefer MS (2016) The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med 17:106–117. https://doi.org/10.1111/hiv.12281

Zhou L, Saksena NK (2013) HIV associated neurocognitive disorders. Infect Dis Rep 5:e8. https://doi.org/10.4081/idr.2013.s1.e8